Cargando…

Sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue

Sulforaphane (SFN) is a phytochemical compound extracted from cruciferous plants, like broccoli or cauliflower. Its isothiocyanate group renders SFN reactive, thus allowing post-translational modification of cellular proteins to regulate their function with the potential for biological and therapeut...

Descripción completa

Detalles Bibliográficos
Autores principales: Rhoden, Alexandra, Friedrich, Felix W., Brandt, Theresa, Raabe, Janice, Schweizer, Michaela, Meisterknecht, Jana, Wittig, Ilka, Ulmer, Bärbel M., Klampe, Birgit, Uebeler, June, Piasecki, Angelika, Lorenz, Kristina, Eschenhagen, Thomas, Hansen, Arne, Cuello, Friederike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056268/
https://www.ncbi.nlm.nih.gov/pubmed/33831709
http://dx.doi.org/10.1016/j.redox.2021.101951
_version_ 1783680617092743168
author Rhoden, Alexandra
Friedrich, Felix W.
Brandt, Theresa
Raabe, Janice
Schweizer, Michaela
Meisterknecht, Jana
Wittig, Ilka
Ulmer, Bärbel M.
Klampe, Birgit
Uebeler, June
Piasecki, Angelika
Lorenz, Kristina
Eschenhagen, Thomas
Hansen, Arne
Cuello, Friederike
author_facet Rhoden, Alexandra
Friedrich, Felix W.
Brandt, Theresa
Raabe, Janice
Schweizer, Michaela
Meisterknecht, Jana
Wittig, Ilka
Ulmer, Bärbel M.
Klampe, Birgit
Uebeler, June
Piasecki, Angelika
Lorenz, Kristina
Eschenhagen, Thomas
Hansen, Arne
Cuello, Friederike
author_sort Rhoden, Alexandra
collection PubMed
description Sulforaphane (SFN) is a phytochemical compound extracted from cruciferous plants, like broccoli or cauliflower. Its isothiocyanate group renders SFN reactive, thus allowing post-translational modification of cellular proteins to regulate their function with the potential for biological and therapeutic actions. SFN and stabilized variants recently received regulatory approval for clinical studies in humans for the treatment of neurological disorders and cancer. Potential unwanted side effects of SFN on heart function have not been investigated yet. The present study characterizes the impact of SFN on cardiomyocyte contractile function in cardiac preparations from neonatal rat, adult mouse and human induced-pluripotent stem cell-derived cardiomyocytes. This revealed a SFN-mediated negative inotropic effect, when administered either acutely or chronically, with an impairment of the Frank-Starling response to stretch activation. A direct effect of SFN on myofilament function was excluded in chemically permeabilized mouse trabeculae. However, SFN pretreatment increased lactate formation and enhanced the mitochondrial production of reactive oxygen species accompanied by a significant reduction in the mitochondrial membrane potential. Transmission electron microscopy revealed disturbed sarcomeric organization and inflated mitochondria with whorled membrane shape in response to SFN exposure. Interestingly, administration of the alternative energy source l-glutamine to the medium that bypasses the uptake route of pyruvate into the mitochondrial tricarboxylic acid cycle improved force development in SFN-treated EHTs, suggesting indeed mitochondrial dysfunction as a contributor of SFN-mediated contractile dysfunction. Taken together, the data from the present study suggest that SFN might impact negatively on cardiac contractility in patients with cardiovascular co-morbidities undergoing SFN supplementation therapy. Therefore, cardiac function should be monitored regularly to avoid the onset of cardiotoxic side effects.
format Online
Article
Text
id pubmed-8056268
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-80562682021-04-23 Sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue Rhoden, Alexandra Friedrich, Felix W. Brandt, Theresa Raabe, Janice Schweizer, Michaela Meisterknecht, Jana Wittig, Ilka Ulmer, Bärbel M. Klampe, Birgit Uebeler, June Piasecki, Angelika Lorenz, Kristina Eschenhagen, Thomas Hansen, Arne Cuello, Friederike Redox Biol Research Paper Sulforaphane (SFN) is a phytochemical compound extracted from cruciferous plants, like broccoli or cauliflower. Its isothiocyanate group renders SFN reactive, thus allowing post-translational modification of cellular proteins to regulate their function with the potential for biological and therapeutic actions. SFN and stabilized variants recently received regulatory approval for clinical studies in humans for the treatment of neurological disorders and cancer. Potential unwanted side effects of SFN on heart function have not been investigated yet. The present study characterizes the impact of SFN on cardiomyocyte contractile function in cardiac preparations from neonatal rat, adult mouse and human induced-pluripotent stem cell-derived cardiomyocytes. This revealed a SFN-mediated negative inotropic effect, when administered either acutely or chronically, with an impairment of the Frank-Starling response to stretch activation. A direct effect of SFN on myofilament function was excluded in chemically permeabilized mouse trabeculae. However, SFN pretreatment increased lactate formation and enhanced the mitochondrial production of reactive oxygen species accompanied by a significant reduction in the mitochondrial membrane potential. Transmission electron microscopy revealed disturbed sarcomeric organization and inflated mitochondria with whorled membrane shape in response to SFN exposure. Interestingly, administration of the alternative energy source l-glutamine to the medium that bypasses the uptake route of pyruvate into the mitochondrial tricarboxylic acid cycle improved force development in SFN-treated EHTs, suggesting indeed mitochondrial dysfunction as a contributor of SFN-mediated contractile dysfunction. Taken together, the data from the present study suggest that SFN might impact negatively on cardiac contractility in patients with cardiovascular co-morbidities undergoing SFN supplementation therapy. Therefore, cardiac function should be monitored regularly to avoid the onset of cardiotoxic side effects. Elsevier 2021-03-31 /pmc/articles/PMC8056268/ /pubmed/33831709 http://dx.doi.org/10.1016/j.redox.2021.101951 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Rhoden, Alexandra
Friedrich, Felix W.
Brandt, Theresa
Raabe, Janice
Schweizer, Michaela
Meisterknecht, Jana
Wittig, Ilka
Ulmer, Bärbel M.
Klampe, Birgit
Uebeler, June
Piasecki, Angelika
Lorenz, Kristina
Eschenhagen, Thomas
Hansen, Arne
Cuello, Friederike
Sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue
title Sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue
title_full Sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue
title_fullStr Sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue
title_full_unstemmed Sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue
title_short Sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue
title_sort sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056268/
https://www.ncbi.nlm.nih.gov/pubmed/33831709
http://dx.doi.org/10.1016/j.redox.2021.101951
work_keys_str_mv AT rhodenalexandra sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue
AT friedrichfelixw sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue
AT brandttheresa sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue
AT raabejanice sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue
AT schweizermichaela sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue
AT meisterknechtjana sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue
AT wittigilka sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue
AT ulmerbarbelm sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue
AT klampebirgit sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue
AT uebelerjune sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue
AT piaseckiangelika sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue
AT lorenzkristina sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue
AT eschenhagenthomas sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue
AT hansenarne sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue
AT cuellofriederike sulforaphaneexposureimpairscontractilityandmitochondrialfunctioninthreedimensionalengineeredhearttissue